Thyroxine changes in COVID-19 pandemic: A systematic review and meta-analysis

Ziqi Li, Pengwei Hou, Shuwen Mu, Renzhi Wang, Hui Miao, Feng Ming, He Wang, Wentai Zhang, Yi‐Hao Chen, Tianshun Feng, Shousen Wang, Yi FangFrontiers in Endocrinology 2023 · DOI

Abstract

Compared with the healthy cohort, COVID-19 patients showed decreased TSH and FT3 and increased FT4, similar to non-COVID-19 pneumonia. Thyroid function changes were related to the severity of COVID-19. Thyroxine levels have clinical significance for prognosis evaluation, especially FT3.

Introduction

While COVID-19 is primarily a respiratory disease, the SARS-CoV-2 virus is known to affect multiple organ systems. The thyroid gland is a potential target because it expresses high levels of the ACE2 receptor, which the virus uses for entry. Early clinical reports on thyroid function were inconsistent; some suggested direct viral damage (thyroiditis), while others pointed toward a systemic stress response. This systematic review and meta-analysis, published in Frontiers in Endocrinology, synthesizes data from 41 studies to map how COVID-19 disrupts the thyroid gland and determine if hormonal shifts can help clinicians predict patient outcomes.

Methods

The authors conducted a systematic review of English and Chinese databases (including PubMed, Embase, and Cochrane) from the start of the pandemic through August 2022. The analysis included 41 observational studies involving 5,873 COVID-19 patients. Researchers compared COVID-19 patients against healthy cohorts and patients with non-COVID-19 pneumonia, stratifying data by disease severity (severe vs. non-severe) and outcome (survivors vs. non-survivors). Statistical analysis utilized Standard Mean Differences (SMD) and 95% confidence intervals.

Figure 1: Flow diagram of the study selection process.

Key Results and Insights

The meta-analysis revealed a consistent "thyroid signature" for COVID-19: significantly lower TSH and FT3 levels ($P < 0.001$) and significantly higher FT4 levels ($P < 0.001$) compared to healthy controls.

The NTIS Signature

This observed pattern—low TSH, low FT3, and slightly elevated FT4—is the classic hallmark of Non-Thyroidal Illness Syndrome (NTIS). This suggests that thyroid disruption in COVID-19 is largely a systemic response to the "cytokine storm" and metabolic stress rather than solely direct viral destruction of the gland. Interestingly, these changes were remarkably similar to those seen in non-COVID-19 pneumonia, implying a generalized reaction to severe respiratory distress.

Figure 2: Forest plots showing Standard Mean Differences (SMD) and 95% CI for thyroid markers.

FT3 as a Prognostic Beacon

Of all the markers studied, Free Triiodothyronine (FT3) showed the most dramatic difference between survivors and non-survivors. Survivors had significantly higher levels of TSH (SMD = 0.29), FT3 (SMD = 1.11), and FT4 (SMD = 0.22). In ICU settings, survivors maintained significantly higher FT3 and FT4 levels than non-survivors, reinforcing their value in triaging high-risk patients. Follow-up data showed that thyroid levels generally returned to normal after the acute phase, supporting the transient, stress-induced nature of the condition.

Limitations and Future Work

The authors acknowledge several limitations, including selection bias from hospital-based studies and significant heterogeneity ($I^2 > 80\%$) in some measurements. While the data points toward NTIS, the study cannot entirely rule out direct viral injury to the pituitary-thyroid axis. Future research is needed to determine if thyroid hormone supplementation could improve outcomes in severe COVID-19 cases, though current clinical guidelines generally advise against it for NTIS. Ultimately, thyroxine levels, especially FT3, have significant clinical value for prognosis evaluation in COVID-19.

Summary updated

Abstract

Compared with the healthy cohort, COVID-19 patients showed decreased TSH and FT3 and increased FT4, similar to non-COVID-19 pneumonia. Thyroid function changes were related to the severity of COVID-19. Thyroxine levels have clinical significance for prognosis evaluation, especially FT3.
BibTeX
@inproceedings{li2023thyroxine,
  author = {Ziqi Li and Pengwei Hou and Shuwen Mu and Renzhi Wang and Hui Miao and Feng Ming and He Wang and Wentai Zhang and Yi‐Hao Chen and Tianshun Feng and Shousen Wang and Yi Fang},
  title = {{Thyroxine changes in COVID-19 pandemic: A systematic review and meta-analysis}},
  booktitle = {Frontiers in Endocrinology},
  year = {2023},
  doi = {10.3389/fendo.2023.1089190},
}
Figure